Sensorium’s groundbreaking platform builds beyond the current landscape of psychedelic compounds and established targets to probe the far-reaching, unexplored chemical space of psychoactive plants and fungi.
Directed by a multidisciplinary team of experts, our unique approach starts with evidence based on human use and focuses on impact in the human brain at every step, ensuring reliable translation of results from the test tube to the clinic.
Bringing together the latest chemistry, neuroscience, and machine learning, our platform has the power to continually identify, reproduce, and enhance naturally occurring psychoactive molecules and optimize these molecules for greater efficacy and safety as modern mental health medicines.
NeuroNatural Library™: Our proprietary library of thousands of psychoactive plants and natural products for molecular screening forms the foundation for our lead discovery work. It was systematically built by curating ethnobotanical history, partnering with global resources to source biospecimens, and employing DNA barcoding to authenticate the samples.
PsychGraph™: Our predictive knowledge network of psychoactive molecules and their potential therapeutic use drives program development and nomination of drug candidates. This growing system continually reveals families of plants and fungi with neuroplasticity-inducing compounds (a central phenotype associated with therapeutic efficacy), as well as pharmacophores, which serve as the basis for building better medicines. Data outputs from the NeuroNatural Library™ and high-throughput characterization feed into proprietary machine learning algorithms, iteratively improving and accelerating the process of drug discovery.
iPSC neuronal assays: We examine molecules of interest in systems that mimic human cell and tissue behavior, with a focus on identifying compounds that induce neuroplasticity. This results in identification of diverse mechanisms of action, more relevant hits from screening, and better translation from preclinical data to clinical trials.